MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Create the #1 medical social network (Video/Pictures)
Global aggregator of choice for advanced medical technology business intelligence
Innovation & Royalty Aggregator
Royalty Pharma plc (NASDAQ:RPRX)
Finance & Acquisitions: Royalty Pharma
Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY)*
Organization & Developments: Alnylam
*Developments: Alnylam
Parents
Organization & Developments: Alnylam
Children
2010: Researchers Try Efforts to Block Gene in Huntington's (2010)
2010: Roche Dumps RNAi, Sends Shock Waves Through Alnylam, Tekmira(2010)
2011: Alnylam and Glaxo Partner on RNAi for Vaccine Production (2011)
2012: Alnylam Cuts One-Third of Workforce, To Save Cash for RNAi Clinical Plans (2012)
2013: Alnylam gets $7M milestone from Genzyme for rare disease drug (2013)
2016: Alnylam plunges after deaths force it to pull PhIII blockbuster candidate revusiran
2016: Alnylam: Multiple Paths Forward Post Revusiran Failure - Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
2017: Alnylam Pharmaceuticals Wins Another Round_seekingalpha
2017: Alnylam Sets Its Eyes On The Finish Line_seekingalpha
2018: Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
2018: Alnylam lands historic FDA OK on patisiran, revving up the first global rollout for an RNAi breakthrough – Endpoints News
2019: Alnylam Pharmaceuticals _Looking for mid-teen return on this mid-cap biotech stock _ gallery.mailchimp.com
2019: Alnylam's Positive Phase 3 Results For Givosiran Pushes It Forward For Regulatory Filings_seekingalpha.com
2019: VA_65--Alnylam Pharmaceuticals, Inc. 65IB
2020: Alnylam nets FDA nod for Oxlumo, its 3rd rare disease drug, and plans unique value-based deals
2020: Alnylam, Vir team up to develop siRNAs to tackle COVID-19
2020: Alnylam's RNAi Therapies Make It A Buy
2021: Alnylam: Potential Is In Line With Current Valuation
2022: Alnylam culls 3 programs, including nephropathy med that was slated for phase 3
2022: Alnylam Pharmaceuticals (ALNY) Investor Presentation - Slideshow_ seekingalpha.com
2022: Alnylam: Good Start For Amvuttra, Unanswered Regulatory Questions On Onpattro_ seekingalpha.com
2022: Alnylam: Onpattro's Position In The ATTR Amyloidosis Cardiomyopathy Market_seekingalpha.com
2023: Alnylam Pharmaceuticals: A Good Buy Ahead Of Phase 3 Data For Vutrisiran
2023: Alnylam Pharmaceuticals: R&D Day Reveals Ambitious Plans_ seekingalpha.com
2023: Alnylam: Q3 Journey, Financial Growth, And Regulatory Hurdles (NASDAQ:ALNY)
2023: Alnylam: Why The FDA Rejection Of Onpattro Is A Minor Setback
2024: Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch
2024: Alnylam Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Alnylam Pharmaceuticals' SWOT analysis: stock poised for growth as ATTR-CM drug shows promise Investing.com
2024: Alnylam says heart drug succeeds in closely watched study
2024: The Promise of RNAi Therapeutics for Cardiovascular Disease Treatment
2024: Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation_seekingalpha.com
2025: 5 FDA decisions to watch in the first quarter of 2025
2025: Alnylam Pharmaceuticals: Commercialization And Early-Stage Studies Are Likely To Drive 2025
2025: Alnylam: Waiting For Regulatory Updates In March
Jumps
*Organization: Alnylam